Matches in Nanopublications for { ?s ?p "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP879515.RADeFUOhm89QfIZ8l2hDuXLZIx906awQz0okyGemKNMVc130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879515.RADeFUOhm89QfIZ8l2hDuXLZIx906awQz0okyGemKNMVc130_provenance.
- NP472343.RA3lNGq--4oaHRHooldhqnQBvABp14XIYw9rP0vQ9jox4130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP472343.RA3lNGq--4oaHRHooldhqnQBvABp14XIYw9rP0vQ9jox4130_provenance.
- NP635951.RAXel_C9xtWrPPa_leDxbsjiJMHDKQizllzrOHar4vac8130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP635951.RAXel_C9xtWrPPa_leDxbsjiJMHDKQizllzrOHar4vac8130_provenance.
- NP472472.RAZhF8IQKfWwOcG268pRITULBTQsVh9FuQ8G8VEmlJ7ZA130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP472472.RAZhF8IQKfWwOcG268pRITULBTQsVh9FuQ8G8VEmlJ7ZA130_provenance.
- NP636120.RA2kqL06DctexqH6Q-w4Jq7vdxvPIBhYoT68oaPItJuxw130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP636120.RA2kqL06DctexqH6Q-w4Jq7vdxvPIBhYoT68oaPItJuxw130_provenance.
- NP879518.RAwxNaJwwMmkheIupNIArH2V5hedJrCkAOI9Xx2CN1M6o130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879518.RAwxNaJwwMmkheIupNIArH2V5hedJrCkAOI9Xx2CN1M6o130_provenance.
- NP879510.RAWNXJoDrfhwjsEZZqOj3GopwU0JSHOSe_8BQc_8WI_sM130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879510.RAWNXJoDrfhwjsEZZqOj3GopwU0JSHOSe_8BQc_8WI_sM130_provenance.
- assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP879519.RAuI0BAciAAhWV_6L8UGKdKbafOvZqDZzVnzTno4lEAj0130_assertion description "[Therapeutic targeting of Oct4(+)/TNC(+) progenitors may counteract the contribution of NB-derived ECs to tumor relapse and chemoresistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879519.RAuI0BAciAAhWV_6L8UGKdKbafOvZqDZzVnzTno4lEAj0130_provenance.